Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms

L.J.H. Brada, M.S. Walma, L.A. Daamen, S. van Roessel, R.M. van Dam, I.H. de Hingh, M.L.S. Liem, V.E. de Meijer, G.A. Patijn, S. Festen, M.W.J. Stommel, K. Bosscha, M.B. Polee, C.Y. Nio, F.J. Wessels, J.J.J. de Vries, K.P. van Lienden, R.C. Bruijnen, M. Los, N.H. MohammadH.W. Wilmink, O.R. Busch, M.G. Besselink, I.Q. Molenaar, H.C. van Santvoort*, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)589-597
Number of pages9
JournalJournal of Surgical Oncology
Volume124
Issue number4
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • chemotherapy
  • FOLFIRINOX
  • locally advanced pancreatic cancer
  • resection
  • survival
  • CARBOHYDRATE ANTIGEN 19-9
  • NEOADJUVANT THERAPY
  • PROGNOSTIC-FACTORS
  • ADENOCARCINOMA
  • GEMCITABINE
  • OUTCOMES
  • CHEMOTHERAPY
  • RADIOTHERAPY
  • COMORBIDITY
  • CRITERIA

Cite this